Flood the airway in minutes, not hours—before the virus spreads.
In the ongoing effort to meet respiratory viruses at the threshold of infection rather than after they have taken hold, researchers in Melbourne have completed a Phase 1 trial of IN-006, an inhaled monoclonal antibody designed to deliver protective concentrations directly to the airways within minutes. Twenty-three healthy adults tolerated the treatment well, with only mild side effects and antibody levels in nasal fluid that far exceeded what intravenous delivery could achieve at comparable speed. The study does not yet prove the drug works in sick patients, but it suggests that the ancient intuition of meeting a threat at the gate — rather than marshaling defenses from within — may now have a clinical form worth pursuing.
- Every hour a respiratory virus goes unchallenged in the airway is ground it may never surrender, and traditional injected antibodies simply cannot arrive fast enough to contest the earliest breach.
- IN-006 — a reformulated version of an existing antibody turned into breathable mist — reached therapeutic concentrations in nasal fluid within 30 minutes of inhalation, a timeline no intravenous drip can match.
- Twenty-three healthy volunteers completed the trial with mostly mild complaints: a sore throat here, a headache there, dizziness in a handful — nothing severe enough to pause the study.
- Antibody levels remained detectable in the bloodstream for weeks, suggesting the inhaled route does not sacrifice systemic protection in exchange for local speed.
- The trial's clean safety profile and simple six-minute delivery — handheld, self-administered — now point the way toward larger studies in patients who actually have COVID-19, where the real test awaits.
When a virus crosses the mucus lining of the airways, time becomes the decisive variable. SARS-CoV-2 moves faster than most intravenous antibody treatments can respond — by the time an injected drug builds meaningful concentrations at the site of infection, the virus has already gained ground. Researchers in Melbourne set out to close that gap by reformulating an existing monoclonal antibody into an inhaled mist called IN-006, capable of reaching the airway in minutes rather than hours.
Between September and December 2021, twenty-three healthy adults aged 18 to 55 participated in the Phase 1 trial. Participants received either a low single dose, a high single dose, or a week of daily high doses, delivered through a handheld vibrating mesh nebulizer in roughly six minutes. Six others received a placebo. The researchers monitored side effects, measured antibody concentrations in nasal fluid and blood, and tracked how long the drug persisted in the body.
The results were encouraging on both fronts. Side effects were mostly mild — sore throats, headaches, occasional dizziness — with only one moderate event across the entire study. More striking were the antibody concentrations: a single 30-milligram dose produced 146 micrograms per milliliter in nasal fluid three hours later, while the higher dose yielded 459. In the multiple-dose group, levels reached 607 micrograms per milliliter just 30 minutes after inhalation. The drug also appeared in the bloodstream within 12 hours and remained above virus-neutralizing thresholds for weeks, with a half-life comparable to the original intravenous formulation.
The study's limits are real: all participants were healthy, the sample was small, and lower airway measurements were not possible under the COVID-19 protocols of the time. But the safety profile was clean, the delivery simple enough for self-administration, and the pharmacokinetics pointed toward a treatment that could offer both local and systemic protection. Larger trials in patients with active COVID-19 will determine whether speed at the gate translates into better outcomes — but the foundation, for now, appears sound.
When a virus infects the lungs, the race is against time and distance. SARS-CoV-2 spreads by crossing the mucus layer that lines the airways, reaching new cells with each breach. Traditional antibody treatments—delivered by injection into muscle or vein—take hours to build meaningful concentrations where they're needed most. By then, the virus has already gained ground.
Researchers at a Melbourne laboratory set out to collapse that timeline. They reformulated an existing monoclonal antibody called regdanvimab, transforming it from an intravenous drug into an inhaled mist. The new version, called IN-006, could theoretically reach the airway in minutes rather than hours, flooding the site of infection with antibodies before the virus could establish a foothold. In late 2021, they tested whether this approach was safe.
Twenty-three healthy adults, aged 18 to 55, participated in the trial between September and December of that year. Some received a single low dose of 30 milligrams, others a single high dose of 90 milligrams, and a third group received 90 milligrams daily for a week. The drug was delivered via a vibrating mesh nebulizer—a handheld device that turns liquid into breathable mist. Six participants received placebo saline instead. The researchers tracked adverse events, measured antibody levels in nasal fluid and blood, and watched how long the drug persisted in the body.
The treatment was well tolerated. Participants completed the inhalation in about six minutes. Among those who received a single dose, eight developed at least one side effect, most commonly a sore throat or headache. Only one adverse event was moderate in severity; the rest were mild. In the multiple-dose group, six participants reported side effects, with dizziness being most common. No one in the placebo group reported problems during the multiple-dose phase. Three participants experienced effects directly linked to the drug itself—sore throat, headache, or cough—but nothing severe enough to halt the trial.
The antibody concentrations told the real story. Three hours after a single 30-milligram dose, nasal fluid contained 146 micrograms per milliliter of IN-006. The 90-milligram dose produced 459 micrograms per milliliter. In the multiple-dose cohort, measured just 30 minutes after inhalation on days one through three, concentrations reached 607 micrograms per milliliter—far higher than the 94 micrograms per milliliter measured three hours later. The drug was detectable in the bloodstream 12 hours after dosing, and serum levels remained elevated for weeks, staying above the threshold needed to neutralize the virus. The half-life in blood ranged from 253 to 402 hours depending on the dose—comparable to the original intravenous formulation.
These numbers matter because they suggest the inhaled approach delivers antibodies where they're needed while maintaining systemic protection. High concentrations in the airway mean the drug can neutralize virus particles before they spread. Detectable serum levels mean the antibody can still work if infection reaches deeper into the lungs. The researchers could not directly measure drug levels in the lower respiratory tract—COVID-19 protocols at the time prevented them from collecting fluid samples via bronchoscopy—but the nasal and blood data pointed toward success.
The study had clear limits. All participants were healthy; no one had COVID-19. The sample was small. Larger trials in actual patients would be needed to prove the drug prevents severe disease or speeds recovery. But the safety profile was clean, the delivery was simple enough for self-administration, and the pharmacokinetics suggested the approach could work. If inhaled monoclonal antibodies prove effective in sick patients, they could offer a faster, easier alternative to intravenous infusions—particularly valuable in the early days of infection, when speed matters most.
Notable Quotes
IN-006 was well tolerated and safe in healthy adults, with high antibody levels detected in nasal fluid and detectable levels in serum.— Study findings published in eBioMedicine
The Hearth Conversation Another angle on the story
Why does it matter that the antibody reaches the airway in minutes instead of hours?
Because the virus is replicating the whole time. If you can flood the site of infection with antibodies before the virus spreads to new cells, you stop it earlier and with less damage. Hours of delay means exponential growth.
But the drug still showed up in the bloodstream. Doesn't that mean it's leaving the lungs?
Some does, yes. But that's actually useful. If the virus reaches deeper into the lungs or enters the bloodstream, you still have antibodies circulating to catch it. You're creating a two-layer defense.
The side effects were mostly sore throat and headache. Why would an inhaled antibody cause those?
The antibody itself is a large protein. Inhaling it irritates the throat and airways. Some people get headaches from the inhalation process itself. These are the kinds of effects you'd expect from any inhaled therapy—not dangerous, just uncomfortable.
They couldn't measure drug levels in the lower lungs. Doesn't that undermine the whole point?
It's a limitation, but not fatal. They measured it in the nasal passages and the blood, which gives you a proxy for what's happening deeper down. A larger trial in actual COVID patients would fill that gap.
So when could this actually be used to treat people?
That's the next phase. This was just safety and tolerability in healthy people. You'd need to test it in patients with mild to moderate COVID, see if it actually prevents progression to severe disease, and compare it to existing treatments. That could take years.